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Abstract Selective adenosine receptor agonists and antagonists
have marked effects on the outcome of cerebral ischemia, and
adenosine receptors are expressed on astrocytes. In this study we
examined the effects of various adenosine receptor agonists on
the production of nitric oxide and the induction of iNOS in
astrocytes activated by LPS/IFN-Q and TNF-K/IL-1L and on the
production of TNF-K. Treatment of the cells with the A2A
receptor agonist CGS 21680 inhibited both NO production and
iNOS expression induced by stimulation with either LPS/IFN-Q
or TNF-K/IL-1L, whereas the A1 and A3 receptor agonists, CPA
and Cl-IB-MECA, respectively, did not have significant
inhibitory effects. The inhibitory effect of the A2A receptor
agonist was antagonized by the specific A2A receptor antagonist
CSC. The A2A agonist also exerted a small inhibitory effect on
the production of TNF-K. Similar inhibitory effects on the
production of NO were obtained by cyclic AMP-elevating
reagents, such as forskolin and dibutyryl cyclic AMP. Our
findings suggest that activation of the A2A receptor inhibits NO
production and iNOS expression likely via increased cAMP.
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1. Introduction
Reactive astrocytes play an important role in immune re-
sponses during infectious, degenerative, and autoimmune dis-
eases of the CNS [1]. Reactive astrocytes are also capable of
producing nitric oxide via activation of the inducible form of
nitric oxide synthetase (iNOS) [2]. The increased levels of NO
are implicated in a variety of pathological conditions includ-
ing neural toxicity in viral and bacterial infections, in auto-
immune diseases of the CNS (Murphy et al., 1993), and in
neurotoxicity in focal cerebral ischemia [3]. The induction of
NO production has been reported to be regulated by LPS and
combinations of in£ammatory cytokines such as TNF-K/IL-
1L or IL-1L/IFN-Q [3^5] and to be inhibited by L-adrenergic
agonists, PGE, dexamethasone, and cytokines such as IL-4,
TGF-L and IL-10 [6,7].
Selective adenosine receptor agonists and antagonists have
marked e¡ects on the outcome of models of cerebral ischemia,
and astroglial adenosine receptors are potentially involved in
these e¡ects. There are four known subtypes of adenosine
receptors, A1, A2A, A2B, and A3 [8]. Acute administration of
the selective A1 agonists, ADAC and CPA [9], or chronic
administration of the selective A3 agonist, IB-MECA [10],
improved hippocampal cell survival following global ischemia
in gerbils, and reduces lethality and impairment of behavior
and learning. In both cases, the selective agonist treatment
reduced the increased level of NOS observed in ischemic gerbil
brains.
Functional adenosine receptors of all four subtypes are
found on astrocytes. Activation of A1 receptors inhibited ad-
enylyl cyclase in type-2 rat astrocytes [11], and in the same
cultures activation of A2A receptors stimulated adenylate cy-
clase [12,13]. Recently, agonists selective for A3 receptors,
such as IB-MECA and Cl-IB-MECA, were found to induce
morphological changes in primary rat astroglial cultures [14]
and to induce cell spreading and reorganization of the actin
cytoskeleton in ADF human astrocytoma cells [15]. A2B re-
ceptor stimulation appeared to increase IL-6 in U373 human
astrocytoma cells [16].
In this study we examined the e¡ects of di¡erent adenosine
agonists on the induction of iNOS and the production of NO
in glial cells stimulated with LPS/IFN-Q or TNF-K/IL-1L. For
these studies we used C6 glial cells, which are used extensively
to study glial cell function due to their similarity to primary
glial cells [17]. We found that activation of the A2A receptors
selectively inhibited NO production and iNOS induction,
probably via an increase in cAMP levels.
2. Materials and methods
2.1. Materials
Monoclonal anti-iNOS antibody was obtained from Transduction
Laboratories (Lexington, KY). Recombinant murine TNF-K, IFN-Q
and IL-1L were obtained from Genzyme (Boston, MA). CPA, CPX,
and CGS 21680 were obtained from Research Biochemicals Interna-
tional (Natick, MA). Cl-IB-MECA and CSC were synthesized as re-
ported [18,19].
2.2. C6 glioma cell cultures
Cells (1U105 cells/ml) were seeded on tissue culture dishes (10 cm)
and were grown in medium consisting of Dulbecco’s modi¢ed Eagle’s
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medium (DMEM) containing 10% heat-inactivated fetal calf serum,
2 mM glutamine, penicillin (50 U/ml), and streptomycin (0.05 mg/ml).
Cells were split once a week by short exposure to 0.25% trypsin. C6
cells were treated with either LPS (1 Wg/ml)/IFN-Q (100 U/ml) or
TNF-K (30 ng/ml)/IL-1L (10 ng/ml) for 24 h in the presence or ab-
sence of adenosine ligands.
2.3. NO production
NO formation was detected by accumulation of nitrite in culture
supernatants using the Griess reaction [20]. Brie£y, 50 ml of culture
medium were incubated with 50 ml of 1% sulfanilamide and 50 ml of
1% N-L-naphthylethylenediamine dihydrochloride in 2.5% H3PO4 at
room temperature for 10 min. Optical density at 540 nm was meas-
ured, and the concentration of nitrite ions was quanti¢ed using
NaNO2 as standard.
2.4. Measurement of TNF-K activity
Supernatants of cortical and cerebellar astrocytes were collected
and levels of TNF-K were determined using a commercial ELISA
kit. The detection level of TNF-K in this assay system was about
5 pg/ml.
2.5. Preparation of cell homogenates
Cells were washed and plates were placed on ice, scraped with a
rubber policeman and centrifuged at 1400 rpm for 10 min. The super-
natants were aspirated and the cell pellets were resuspended in 100 ml
of lysis bu¡er (25 mM Tris-HCl, pH 7.4, 50 mM NaCl, 0.5% sodium
deoxycholate; 2% NP-40; 0.2% SDS; 1 mM PMSF; 50 Wg/ml apro-
tinin; 50 WM leupeptin; 0.5 mM Na3VO4) on ice for 15 min. The cell
lysates were centrifuged for 15 min at 14 000 rpm in an Eppendorf
microcentrifuge, supernatants were removed and 2Usample bu¡er
was added.
2.6. Immunoblot analysis
Lysates (20 Wg protein) were resolved by SDS-PAGE (10%) and
were transferred to nitrocellulose membranes. The membranes were
blocked with 5% dry milk in phosphate-bu¡ered saline and subse-
quently stained with the primary antibody. Speci¢c reactive bands
were detected using a goat anti-rabbit or goat anti-mouse IgG con-
jugated to horseradish peroxidase (BioRad, Hercules, CA) and the
immunoreactive bands were visualized by the ECL Western blotting
detection kit (Amersham, Arlington Heights, IL).
3. Results
3.1. NO production
As already reported, we found that C6 glioma cells pro-
duced increased levels of NO in response to LPS/IFN-Q [21].
Pre-treatment of the cells for 1 h with the A2A receptor ago-
nist CGS 21680 and LPS/IFN-Q exerted a dose-dependent in-
hibitory e¡ect on NO production with an IC50 of 0.3 WM (Fig.
1A), whereas CGS 21680 itself had no e¡ect on the produc-
tion of NO by C6 cells. A lesser inhibitory e¡ect were ob-
served in cells treated concomitantly with the A2A agonist and
LPS/IFN-Q (data not shown). We also examined the e¡ects of
CGS 21680 on NO production in C6 cells stimulated with
TNF-K/IL-1L and found similar inhibitory e¡ects (Fig. 1B).
The inhibitory e¡ect of the A2A agonist on NO production
in cells stimulated with either stimuli was partially blocked in
the presence of 10 WM of the speci¢c A2A antagonist, CSC
(Fig. 1A). The inhibitory e¡ect was selective to the A2A re-
ceptor agonist, since the A1 and A3 receptor agonists, CPA (1
or 5 WM) and Cl-IB-MECA (1 or 10 WM), respectively, did
not have signi¢cant inhibitory e¡ects on NO production in
cells stimulated with either LPS/IFN-Q or TNF-K/IL-1L (Fig.
1B).
Since A2A agonists have been shown to increase cAMP
levels in various cell types, including astrocytes [13,20], we
examined the e¡ects of cAMP-elevating agents on NO pro-
duction in our system. As presented in Fig. 1C, forskolin and
db-cAMP inhibited NO production in cells stimulated by both
stimuli.
3.2. iNOS induction
The inhibition of NO secretion in C6 cells by the A2A ago-
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Fig. 1. E¡ects of adenosine receptor agonists and cAMP-elevating
agents on NO production in C6 glioma cells. C6 cells were treated
with LPS/IFN-Q and di¡erent concentrations of CGS 21680 in the
absence (broken line) and presence (solid line) of the A2A antagonist
CSC at a concentration of 10 WM, **P6 0.001, *P6 0.01. A: C6
cells were treated with either LPS/IFN-Q (open bars) or TNF-K/IL-
1L (shaded bars) for 24 h in the absence (labeled medium) or pres-
ence of A1 (CPA, 1 WM), A2A (CGS 21680, 10 WM), or A3 (Cl-IB-
MECA, 1 WM) agonists, **P6 0.001, *P6 0.003 (B), or in the pres-
ence of cAMP-elevating agents, forskolin (10 WM) and db-cAMP
(100 WM), *P6 0.004 (C). Supernatants were collected for the deter-
mination of NO32 . Results represent the means þ S.D. of three sepa-
rate experiments.
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nist CGS 21680 could be due to inhibition of the induction of
iNOS protein. To explore this possibility, we pre-treated cells
with CGS 21680 for 1 h followed by treatment with either
LPS/IFN-Q or TNF-K/IL-1L for an additional 24 h. Whole
cell lysates were analyzed by Western blotting using an anti-
iNOS speci¢c antibody. Fig. 2A shows that cells treated with
LPS/IFN-Q for 24 h exhibited a pronounced increase in the
expression of the iNOS protein. Pre-treatment of the cells with
CGS 21680 reduced the expression of iNOS by 70%, and this
inhibition was blocked by the receptor antagonist CSC. iNOS
induction was also inhibited by db-cAMP. A similar inhibi-
tory e¡ect was observed in cells stimulated with TNF-K/IL-1L
(Fig. 2B). Neither CPA nor Cl-IB-MECA (1 WM) had a sig-
ni¢cant inhibitory e¡ect on iNOS expression (data not
shown).
3.3. TNF-K production
LPS-treated astrocytes are known to secrete cytokines such
as IL-6 and TNF-K [22]. Since TNF-K is a possible mediator
of LPS e¡ects on the production of NO, we examined whether
the inhibitory e¡ect of the A2A agonist CGS 21680 is medi-
ated by inhibiting the secretion of this cytokine in LPS-treated
astrocytes. Fig. 3 shows that treatment of the cells with LPS
induced a large increase in TNF-K secretion following 48 h of
treatment. Treatment of the cells with CGS 21680 induced a
small inhibitory e¡ect on TNF-K secretion. A similar small
inhibitory e¡ect was induced by db-cAMP. The A1 and A3
selective agonists, CPA and Cl-IB-MECA, did not have sig-
ni¢cant e¡ects on secretion of TNF-K (Fig. 3) or IL-6 (data
not shown).
4. Discussion
During the course of brain trauma and in£ammation there
is induction of iNOS by astrocytes. These cells can produce
high levels of NO, which play a role in host defense in the
CNS [2]. Since NO mediates neuronal cell injury, the regula-
tion of its production in the CNS must be well controlled. At
least three cytokines are known to inhibit the induction of NO
in astrocytes and microglial cells, TGF-L, IL-10 and IL-4
[6,7,23]. In addition, increases in intracellular cAMP have
been reported to inhibit the induction of NO by LPS stimu-
lation [24].
We found that the A2A agonist CGS 21680 inhibited NO
production in astrocytes stimulated by either LPS/IFN-Q or
TNF-K/IL-1L. In contrast, activation of the A1 and A3 ad-
enosine receptors did not alter the production of NO or the
induction of iNOS by the di¡erent stimuli. The inhibition of
NO production by the A2A agonist was due to inhibition of
iNOS protein expression. The inhibitory e¡ect was mediated
through activation of the A2A receptor since CGS 21680 is a
selective agonist for A2A adenosine receptors vs. the other
three subtypes. Moreover, the inhibitory e¡ect was blocked
by CSC, a selective A2A antagonist, which further supports
the speci¢c involvement of the A2A receptor in C6 cells.
The inhibitory e¡ect of CGS 21680 on NO production was
due to the inhibition of iNOS expression by stimulated astro-
cytes. The expression of iNOS in glial cells is induced by LPS,
IFN-Q, TNF-K, IL-1 and phorbol esters [7], and activation of
this enzyme leads to the production of high amounts of NO
for prolonged periods of times. The expression of iNOS has
been reported to be negatively regulated by L-adrenergic ago-
nists, IL-4, IL-10, TGF-L, dexamethasone, and cAMP, and by
NO itself [24].
The mechanism by which the A2A agonist inhibits NO pro-
duction and iNOS induction is probably associated with an
increased level of cAMP. Indeed, elevation of cAMP by either
forskolin or db-cAMP inhibited NO production [24], and fac-
tors which activate adenylyl cyclase such as endothelin have
been reported to inhibit NO production in cultured astrocytes
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Fig. 3. E¡ect of adenosine agonists selective for A1 (CPA, 1 WM),
A2A (CGS 21680, 10 WM), or A3 (Cl-IB-MECA, 1 WM) receptors
and db-cAMP (100 WM) on TNF-K secretion in LPS/IFN-Q-treated
cells. C6 glioma cells were treated with LPS/IFN-Q in the presence
and absence of di¡erent adenosine agonists and db-cAMP, and
TNF-K levels were determined following 48 h using an ELISA kit.
The results represent means þ S.D. from three separate experiments.
*P6 0.002, **P6 0.01.
Fig. 2. E¡ect of the A2A receptor agonist CGS 21680 and db-cAMP
on iNOS induction. Cells were stimulated with either LPS/IFN-Q
(A) or with TNF-K/IL-1L (B) for 24 h in the absence and presence
of CGS 21680 (10 WM), CSC (10 WM) or db-cAMP (100 WM).
Whole cell lysates were resolved by SDS-PAGE and proteins were
immunoblotted with anti-iNOS antibody. The results are of one rep-
resentative experiment out of three.
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[25]. The e¡ect of the A2A agonist does not seem to be medi-
ated by a decrease in TNF-K secretion, since the secretion of
this cytokine was a¡ected to a small degree by treatment with
the A2A agonist. The e¡ects of adenosine agonists on iNOS
induction and NO production in the brain have not been
described so far. Interestingly, activation of the A2A adenosine
receptor has been reported to increase NO production in vas-
cular smooth muscle cells [26]. However, in these cells, in
contrast to glial cells, increases in cAMP induce activation
of NO production.
Adenosine has been shown to be secreted during ischemic
conditions in the brain. The roles of the di¡erent adenosine
receptors have been associated with either neuronal protection
or neurotoxicity depending on the concentrations of the ad-
enosine and on the speci¢c receptor being activated. Our re-
sults indicate that activation of the A2A adenosine receptor
could inhibit NO production by astrocytes during in£amma-
tory conditions in the CNS. In addition, since iNOS has also
been also implicated in cerebral ischemic damage [27], activa-
tion of the A2A receptor may play a role in protecting against
neural toxicity during ischemic conditions in the CNS.
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